Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

This study found that among men unresponsive to finasteride for androgenic alopecia, 56.25% showed significant hair improvement after six months of dutasteride treatment with reasonable adverse effects.

This study concluded that dutasteride modestly reduces nocturia in men but does not improve sleep quality.

Dutasteride helps reduce male pattern hair loss, but may cause side effects like altered libido and erectile dysfunction.

This meta-analysis found that while both Dienogest and GnRH analogues effectively managed endometriosis-related pain, Dienogest reduced recurrence rates and hot flushes but increased irregular bleeding, making it a safer option due to fewer side effects.

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

This study reviewed the pharmacological properties of fesoterodine and found that its ability to effectively treat overactive bladder, especially in the elderly, is likely due to its specific properties, including its receptor affinity, blood-brain barrier penetration, metabolic conversion, and extended-release formulation.

This study classified dutasteride, fesoterodine, and finasteride as beneficial for older or frail elderly patients, while suggesting caution or avoidance of α-blockers and antimuscarinics in this group.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

Dutasteride may become the top choice for treating hair loss.

This report analyzed an FDA adverse event database and aimed to evaluate and describe post-finasteride syndrome potentially related to dutasteride, but it does not report new clinical findings.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

In this study, daily administration of 100mg DHEA for 16 weeks in women with adequate ovarian reserve did not modify metabolic or reproductive variables, apart from increased antral follicular count and anti-Müllerian hormone levels.

This study found that dutasteride is not associated with an increased risk of osteoporosis or fractures in older men compared to finasteride, suggesting dutasteride does not adversely affect bone health.

This study found that five 0.1 mg dutasteride capsules are bioequivalent to one 0.5 mg dutasteride capsule in healthy adult males under fasting conditions, and both were well tolerated.

Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.